File(s) under permanent embargo
Antidepressants in inflammatory bowel disease: a systematic review
journal contribution
posted on 2017-03-06, 00:00 authored by B J D Macer, Antonina Mikocka-WalusAntonina Mikocka-Walus, S PradyBackground: Antidepressants are commonly used to treat symptoms of anxiety and depression in inflammatory bowel disease (IBD). Recent studies suggest a link between IBD activity and an individual’s emotional state which raises the possibility that antidepressants may potentially modify the disease course of IBD. This systematic review thus primarily aims to evaluate the efficacy of antidepressants on IBD activity, and secondarily, on anxiety and depression.
Methods: MEDLINE, EMBASE, Cochrane (IBD Group), CINAHL, AMED, PsycINFO and Open Grey were searched from 1990 onwards with no restrictions on study design. A quality appraisal was conducted using several scales as appropriate for each study design. A narrative synthesis was also conducted.
Results: Fifteen eligible studies included in the review (1 RCT, 2 cohorts, 1 case-control, 1 cross-sectional survey, 1 qualitative, 2 audits, 1 case-series and 6 case reports) examined a range of antidepressants. Twelve studies suggested antidepressants have a positive impact on IBD course. Nine studies reported anxiety and depression as an outcome, of these eight reported beneficial effects of antidepressants. Most of the studies were deemed to be at low risk of bias, apart from the case reports, which were at high risk of bias.
Conclusions: The current research indicates antidepressants may have a beneficial effect on IBD course. However, it is currently not possible to determine their efficacy for certain due the lack of randomised trials. Further trials using objective measures of IBD activity, longer follow-up periods and larger sample sizes are needed.
Methods: MEDLINE, EMBASE, Cochrane (IBD Group), CINAHL, AMED, PsycINFO and Open Grey were searched from 1990 onwards with no restrictions on study design. A quality appraisal was conducted using several scales as appropriate for each study design. A narrative synthesis was also conducted.
Results: Fifteen eligible studies included in the review (1 RCT, 2 cohorts, 1 case-control, 1 cross-sectional survey, 1 qualitative, 2 audits, 1 case-series and 6 case reports) examined a range of antidepressants. Twelve studies suggested antidepressants have a positive impact on IBD course. Nine studies reported anxiety and depression as an outcome, of these eight reported beneficial effects of antidepressants. Most of the studies were deemed to be at low risk of bias, apart from the case reports, which were at high risk of bias.
Conclusions: The current research indicates antidepressants may have a beneficial effect on IBD course. However, it is currently not possible to determine their efficacy for certain due the lack of randomised trials. Further trials using objective measures of IBD activity, longer follow-up periods and larger sample sizes are needed.
History
Journal
Inflammatory bowel diseasesVolume
23Issue
4Pagination
534 - 550Publisher
Lippincott Williams & WilkinsLocation
Philadelphia, Pa.Publisher DOI
ISSN
1078-0998Language
engPublication classification
C Journal article; C1 Refereed article in a scholarly journalCopyright notice
2017, Crohn's & Colitis Foundation of AmericaUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC